v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
 3 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 60,000 95,157
General and administrative 946,708 753,148
Total operating expenses 1,006,708 848,305
Loss from operations (1,006,708) (848,305)
Other income (expense):    
Interest income 166,278 217,793
Dividend income 240,884 0
Change in fair value of warrant liability 4,221,000 243,000
Change in fair value of derivative liability 597,000 0
Change in fair value of convertible note receivable – Femasys 0 912,000
Change in fair value of warrant asset – Femasys (414,000) (1,215,000)
Change in fair value of investment – QCLS (5,550,000) (2,839,000)
Change in fair value of warrant assets – QCLS (3,181,000) (4,832,000)
Gain on legal settlement – re-fair value of warrants 0 106,000
Unrealized loss on marketable securities (154,548) (104,463)
Other expense, net (97) (121)
Total other income (expense), net (4,074,483) (7,511,791)
Income tax benefit (expense) 0 0
Net loss (5,081,191) (8,360,096)
Preferred stock dividends (83,399) 0
Preferred stock accretion (621,217) 0
Net loss attributable to common stockholders $ (5,785,807) $ (8,360,096)
Basic income (loss) per share attributable to common stockholders $ (0.54) $ (1.23)
Diluted income (loss) per share attributable to common stockholders $ (0.54) $ (1.23)
Weighted average shares outstanding basic 10,735,649 6,795,779
Weighted average shares outstanding diluted 10,735,649 6,795,779